Get started
Author

Yazan K. Barqawi

Observed names: Y Barqawi, Y. Barqawi, Y. K. Barqawi, Yazan Barqawi, Yazan K Barqawi
Observed institutions: University of New Mexico, AbbVie (United States), Al Ain Hospital, Abu Dhabi Health Services, AstraZeneca (United States), University of New Mexico Health Sciences Center
ORCID: 0000-0002-3045-6813
Observed ORCID: 0000-0002-3045-6813
OpenAlex ID: A5065537882
Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance
2019 · Yazan K. Barqawi, Matthew E. Borrego, et al. · Journal of Medical Economics · 31
PDF
Immune-Mediated and Psychiatric Comorbidities Among Patients Newly Diagnosed With Alopecia Areata
2024 · Arash Mostaghimi, Ahmed M. Soliman, et al. · JAMA Dermatology · 23
Novel oral anticoagulants and the 73rd anniversary of historical warfarin
2015 · Abdulla Shehab, Asim Ahmed Elnour, et al. · Journal of the Saudi Heart Association · 20
PDF
Association Between Biologic Exposure and the Risk of Depression in Patients with Psoriasis: A Retrospective Analysis of Large US Administrative Claims Data
2024 · Bruce Strober, Ahmed M. Soliman, et al. · American Journal of Clinical Dermatology · 8
Community–Clinical Linkages: The Effects of the Healthy Here Wellness Referral Center on Chronic Disease Indicators Among Underserved Populations in New Mexico
2022 · Theresa H. Cruz, Blake Boursaw, et al. · Health Promotion Practice · 4
Cost impact of Bruton’s tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia
2025 · Adam S Kittai, Dipen A Patel, et al. · Journal of Comparative Effectiveness Research · 3
PDF
Cardiovascular safety outcomes of chronic lymphocytic leukemia treatments: A systematic and targeted literature review
2025 · Yen-Chou Chen, Paulo Miranda, et al. · Critical Reviews in Oncology/Hematology · 2
Clinical Impact of Digital Health Interventions with Educational Components for Patients with Heart Failure: A Systematic Review and Meta-Analysis
2026 · Mohammad Alashqar, Yazan Barqawi, et al. · Healthcare · 1
269 | Real‐world Treatment Patterns and Outcomes Among Patients With Treatment‐naive Mantle Cell Lymphoma in the Uk, Sweden, and France
2025 · M. Cheminant, Y. K. Barqawi, et al. · Hematological Oncology · 1
PDF
Racial and ethnic differences in the receipt of metabolic syndrome risk factor screening and treatment among individuals with prostate cancer treated with androgen deprivation therapy.
2024 · Yazan K. Barqawi, Matthew E Borrego, et al. · Journal of Clinical Oncology · 1
Assessment of components included in published societal perspective or QALY outcome economic analyses for antiepileptic drug treatment in chronic epilepsy
2018 · Melissa H. Roberts, Mikiko Y. Takeda, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 1
ALL-221: Healthcare Resource Use and Economic Burden of B-Cell Acute Lymphoblastic Leukemia for Patients in the United States
2026 · Neil D Palmisiano, Yazan K Barqawi, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: ALL-221: Healthcare Resource Use and Economic Burden of B-Cell Acute Lymphoblastic Leukemia for Patients in the United States
2026 · Neil D Palmisiano, Yazan K Barqawi, et al. · Clinical Lymphoma Myeloma & Leukemia
Racial and ethnic disparities in metabolic syndrome care among prostate cancer patients on androgen deprivation therapy
2026 · Yazan K. Barqawi, Krishna Rekha Moturi, et al. · Cancer Treatment and Research Communications
PDF
Use and outcomes following blinatumomab rechallenge in adolescents and young adults (AYA) and adults with B-cell acute lymphoblastic leukemia (B-ALL)
2025 · Michaela Liedtke, Nikesh Shah, et al. · Blood
PDF
270 | Real‐world Treatment Patterns and Outcomes in High‐risk, Treatment‐naive Mantle Cell Lymphoma: a Multinational Analysis From the Uk, Sweden, and France
2025 · A. Smith, V. Otero, et al. · Hematological Oncology
PDF
Unmet need in adults and adolescents and young adults (AYAs) with B-cell acute lymphoblastic leukemia (B-ALL) in the US following a second relapse.
2025 · Mark Blaine Geyer, Michaela Liedtke, et al. · Journal of Clinical Oncology
HSD19 Longitudinal Changes in Metabolic Syndrome Risk Factors (MSRF) Screening and Treatment Rates Between 2010 and 2021 Among Patients With Prostate Cancer (PCa) Treated With Androgen Deprivation Therapy (ADT)
2024 · M Borrego, Y Barqawi, et al. · Value in Health
PDF
Cost-Offset Analysis Performed Utilizing Covalent Bruton's Tyrosine Kinase Inhibitors Safety Profiles Among Medicare Patients with Chronic Lymphocytic Leukemia
2024 · Adam S Kittai, Dipen A. Patel, et al. · Blood
PDF
50629 Impact of Achieving F-VASI 75 or T-VASI 50 on Patient- and Physician-Reported Outcomes in Patients With Non-Segmental Vitiligo (NSV) Receiving Upadacitinib During a Phase 2 Study
2024 · David Rosmarin, Ahmed M. Soliman, et al. · Journal of the American Academy of Dermatology
Pcn101 Cost Effectiveness Analysis Comparing Enzalutamide, Abiraterone Plus Prednisone and Cabazitaxel Plus Predinsone for the Treatment of Visceral Metastatic Castration Resistant Prostate Cancer (mcrpc) Post Docetaxel Failure
2019 · Y. Barqawi, M. Borrego, et al. · Value in Health
Cost-effectiveness analysis of Enzalutamide, Abiraterone acetate plus prednisone, Cabazitaxel plus prednisone for the treatment of visceral metastatic Castration Resistant Prostate Cancer (mCRPC) after Docetaxel therapy
2018 · Yazan K. Barqawi · UNM’s Digital Repository (University of New Mexico)
PDF
Cost Effectiveness Analysis of Enzalutamide, Abiraterone Plus Prednisone and Cabazitaxel Plus Predinsone for the Treatment of Visceral Metastatic Castration Resistant Prostate Cancer (mcrpc) After Docetaxel Therapy
2018 · Yazan K. Barqawi · UNM’s Digital Repository (University of New Mexico)
Works count: 23
Citation count: 95
H-index: 4
I10-index: 3
Year
Topic
Type